Experimental infection of indigenous North African goats with goatpox virus

Jihane Hamdi1*, Zahra Bamouh1, Mohammed Jazouli1, Meryem Alhyane1, Najet Safini1, Khalid Omari Tadlaoui1, Ouafaa Fassi Fihri2 and Mehdi El Harrak1

Abstract

Background: Goatpox is a viral disease caused by infection with goatpox virus (GTPV) of the genus Capripoxvirus, Poxviridae family. Capripoxviruses cause serious disease to livestock and contribute to huge economic losses. Goatpox and sheeppox are endemic to Africa, particularly north of the Equator, the Middle East and many parts of Asia. GTPV and sheeppox virus are considered host-specific; however, both strains can cause clinical disease in either goats or sheep with more severe disease in the homologous species and mild or sub-clinical infection in the other. Goatpox has never been reported in Morocco, Algeria or Tunisia despite the huge population of goats living in proximity with sheep in those countries. To evaluate the susceptibility and pathogenicity of indigenous North African goats to GTPV infection, we experimentally inoculated eight locally bred goats with a virulent Vietnamese isolate of GTPV. Two uninfected goats were kept as controls. Clinical examination was carried out daily and blood was sampled for virology and for investigating the antibody response. After necropsy, tissues were collected and assessed for viral DNA using real-time PCR.

Results: Following the experimental infection, all inoculated goats displayed clinical signs characteristic of goatpox including varying degrees of hyperthermia, loss of appetite, inactivity and cutaneous lesions. The infection severely affected three of the infected animals while moderate to mild disease was noticed in the remaining goats. A high antibody response was developed. High viral DNA loads were detected in skin crusts and nodules, and subcutaneous tissue at the injection site with cycle threshold (Ct) values ranging from 14.6 to 22.9, while lower viral loads were found in liver and lung (Ct = 35.7 and 35.1). The results confirmed subcutaneous tropism of the virus.

Conclusion: Clinical signs of goatpox were reproduced in indigenous North African goats and confirmed a high susceptibility of the North African goat breed to GTPV infection. A clinical scoring system is proposed that can be applied in GTPV vaccine efficacy studies.

Keywords: Clinical scoring, Experimental infection, Goatpox, Pathogenicity
severe clinical signs in one species and less severe disease in the other [3–5].

Goatpox cause economic losses through mortality, decline in milk yield, damage to hides and trade restrictions [6, 7]. Transmission of GTPV is direct between animals, through respiratory aerosols due to close contact between infected and naïve animals. GTPV may also spread by contamination of abrasions and other skin lesion [3], and experiments have shown that mechanical transmission by flies may occur [8, 9].

After an incubation period of 5 to 14 days, GTPV infected goats develop fever, loss of appetite, depression, ocular and nasal discharge and “pox lesions”. The cutaneous pox lesions develop on the head, mouth, fore and hind limbs, and over hairless parts of the body. They progress through macular, papular, vesicular and pustular stages until scabs are formed. Papules can develop in the mucous membranes. Lesions are mainly observed in the skin, oronasal surfaces, gastrointestinal tract and lungs, but can also be seen in conjunctiva, vulva, prepuce, scrotum and udder [10–12]. Papules in conjunctiva and nasal cavity may ulcerate and be accompanied by a mucopurulent discharge. The most severely affected animals may develop pneumonia and mastitis and pregnant females may abort. Secondary bacterial infections are also common and death may occur at any stage of the disease [10].

Alike infection with SPPV, morbidity and mortality rates due to GTPV infection depend on the breed, virus strain and immunity. Mild infections are common among indigenous breeds in endemic areas, but the morbidity can reach 70–90% with a mortality ranging from 5 to 10%. Severe disease with morbidity and mortality of up to 100% may occur in young, stressed and naïve animals [13]. The virus is highly stable, persisting in the environment for up to six months [14].

Goatpox and sheeppox occur in Africa north of the Equator, the Middle East and many parts of Asia, including Afghanistan, Kyrgyzstan, Pakistan, Kazakhstan, India, Nepal and parts of China, and the Russian Federation [15, 16]. In North Africa, goats represent 18% of the small ruminant population, i.e., around 12 million goats [17]. Despite the large population of goats and clinical surveillance programs established in North Africa, no cases of goatpox have been identified [18–21]. This may be due to the absence of circulating virulent GTPV strains in the region, natural resistance of the indigenous goat breeds or absence of transmission of SPPV from sheep to goats.

In this study, we experimentally inoculated indigenous North African goats with a virulent isolate of GTPV to (1) assess the susceptibility of local goat breeds to virulent GTPV, (2) develop a clinical scoring system and (3) examine the antibody response and viral load.

Methods

GTPV inoculation of the goats was carried out in accordance with international guidelines for care and handling of experimental animals, chapter 7.8 of the Territorial Animal Health Code and Directive 2010/63/UE of the European Commission [22, 23]. The protocol was approved by the Internal Ethic Committee for Animal Experiment at Multi-Chemical Industry Santé Animale (2018-MCI-013).

Viral isolate

The virulent isolate of GTPV was provided by the Pirbright Laboratory (Vietnamese strain, isolated from lung tissue from a naturally GTPV infected goat in 2004). The virus was passed three times on chorio-allantoic membranes of fertilized hen’s eggs according to Munyanduki et al. [24], followed by three passages on primary testis cells, maintained in Dulbecco’s Modified Eagle’s Medium with 10% irradiated fetal calf serum [25]. The viral suspension was harvested after five days of incubation at 35 °C. The inoculum had a titre of 105.4 50% tissue culture infective doses (TCID 50) per mL.

Animals

Six months old locally bred North African male goats (n = 10), of around 30 kg body weight, that were raised specifically for experimentation, were housed in an animal biological safety level 3 containment facility in Morocco, were fed a complete balanced diet and had access to water ad libitum. The goats were divided into two groups (8 inoculated goats and 2 negative controls), and housed in separate isolation boxes. The goats were prescreened and found to be negative for GTPV specific antibodies by a virus neutralization test (VNT) as explained below. The goats were kept for 5 days for acclimatization before starting the experiment.

Study design

Eight goats were inoculated subcutaneously in the right side of the neck with 0.5 mL of GTPV inoculum. Two control animals were injected subcutaneously with 0.5 mL of phosphate buffered saline (PBS) solution as placebo. The goats were observed daily for clinical signs and skin lesions until euthanasia. Rectal temperatures were taken daily until 14 days post-infection (pi). Semi-quantitative clinical scoring was done to evaluate the clinical expression and development of skin lesions. The clinical scoring system ranged from 0 to 2, 3 or 5 based on the severity of behavioral changes, rectal temperature, injection site alteration, feed intake, size and distribution of cutaneous lesions and presence and amount/character of oculo-nasal discharge (Table 1). A total cumulative clinical score was made per animal each day, with a possible
maximum daily score of 23. Humane end-points were defined before starting the experiment. To avoid suffering animals were euthanized following appearance and persistence for 24 h of absence of feeding/watering and inactivity or aggravation of lesions (humane end-points). Animals were euthanized by anesthesia through intravenous application of xylazine and intramuscular injection of ketamine followed by exsanguination. Animals not reaching the humane end-points were euthanized at the end of the study (day 18 pi) in a similar way.

For serology, blood samples were collected in plain vacuum tubes via jugular venipuncture using an 18-G needle at day 7 and 14 pi. Tubes were then placed in vertical position at room temperature for 1 h. After clotting, blood was centrifuged at 1500 rounds per minute (RPM) for 15 min, serum was collected, aliquoted and stored at -20 °C until analysis. Whole blood samples were collected in EDTA tubes every third day until day 12 pi and kept at 4 °C until analysis.

**Serology**

Sera were analyzed by VNT as described in the OIE Terrestrial Manual [26]. Sera were heat- inactivated at 56 °C for 30 min and serial 1:3 dilutions of serum were mixed with a constant dose of GTPV (2.5 log$_{10}$) and incubated for 1 h at 37 °C. The serial dilutions were then inoculated onto lamb testis cell suspensions and incubated for 7 days at 37 °C with 5% of CO$_2$, for observation of neutralization of cytopathic effect (CPE). The neutralizing antibody titer was calculated in adherence with the Reed and Muench method [27], which determines 50% end-point by serial dilution using the following formula: 

\[
\log_{10} 50\% \text{ end point dilution} = \log_{10} \text{of dilution showing 50\% of infected cell cultures} - (\text{difference of logarithms} \times \logarithm \text{of dilution factor}) [27].
\]

**Necropsy**

The goats were necropsied and tissue specimens were sampled for virology. These consisted of subcutaneous tissue at the injection site (primary nodule), cutaneous lesions not related to injection site (secondary nodules in the skin), cutaneous crusts overlaying secondary nodules, trachea, lung, heart, liver, spleen, testis, rumen, abomasum, reticulum, omasum, duodenum, kidney, pulmonary and mesenteric lymph nodes.

**Virology**

Collected tissues were minced using sterile scissors and grounded after adding 2 volumes of PBS with 5% penicillin and streptomycin. The suspension was then centrifuged at 3500 RPM for 30 min. The supernatant was aliquoted and stored at −80 °C for real-time polymerase chain reaction (RT-PCR) and virus isolation.

Viral DNA was extracted from the tissue samples and blood using ISOLATE II Genomic DNA Kit (Bioline, London, UK). Samples were evaluated using a quantitative polymerase chain reaction (qPCR) TaqMan assay that amplified and detected 89 bp region from open reading frame 074 which encodes the intracellular mature virion envelope protein P32 within SPPV, GTPV and LSDV [2, 28]. Real-time PCR was conducted with the

### Table 1 Scoring of clinical signs and skin lesions after experimental subcutaneous goatpox virus inoculation

| Clinical signs                          | Score |
|----------------------------------------|-------|
| General behavior                       |       |
| Normal                                 | 0     |
| Stillness                              | 1     |
| Get up when approached                 | 2     |
| Recumbent                              | 3     |
| Feed intake                            |       |
| Normal                                 | 0     |
| Reduce appetite                        | 1     |
| Anorexia                               | 2     |
| Anorexia and not drinking              | 3     |
| Nodule at injection site               |       |
| Absent                                 | 0     |
| Small (1–2 cm)                         | 1     |
| Medium (2–3 cm)                        | 2     |
| Large (> 3 cm)                         | 3     |
| Temperature (°C)                       |       |
| < 39.5                                 | 0     |
| 39.5 ≤ T < 40.0                        | 1     |
| 40.0 ≤ T < 40.5                        | 2     |
| 40.5 ≤ T < 41.0                        | 3     |
| T ≥ 41.0                               | 4     |
| Cutaneous lesions                      |       |
| Absent                                 | 0     |
| Single nodule < 5 mm                   | 1     |
| Single nodule > 10 mm                  | 2     |
| Small nodules in head/flank            | 3     |
| Generalized nodules < 10 mm            | 4     |
| Generalized nodules ≥ 10 mm            | 5     |
| Oculo-nasal discharge                  |       |
| Normal                                 | 0     |
| Mild and watery                        | 1     |
| Serous and profuse                     | 2     |
| Muco-purulent                          | 3     |
| Salivation                             |       |
| Normal                                 | 0     |
| Moderate                               | 1     |
| Profuse                                | 2     |
TaqMan Universal PCR Master Mix Kit (Applied Biosystems, Foster City, CA, USA). The reaction was performed in 96-well optical reaction plates, containing: 12.5 µL of 2 × TaqMan Universal PCR Master Mix, Real-time PCR buffer, 1 µL of each primer Forward 5′-AAA ACG GTA TAT GGA ATA GAG TTG GAA-3′ and Reverse 5′-AAA TGA AAC CAA TGG ATG GGA TA-3′ (10 µM), 0.5 µL of probe FAM-TGG CTC ATA GAT TTC CT-MGB (10 µM) [29], 5 µL of template (DNA) and 5 µL nuclease free water.

The qPCR assay was run in ABI7500 (Applied Biosystems) with the following cycling conditions: 95 °C for 10 min, followed by 40 cycles of PCR at 95 °C for 15 s and 60 °C for 1 min.

The viral inoculum was validated by inoculation of viral dilutions on lamb testis cells and observation of CPE after 7 days of incubation at 37 °C in an atmosphere containing 5% CO₂.

Viral isolation was also attempted from subcutaneous tissue of one of the affected goats (no 335), using 80% confluent lamb testis cells permissive to capripoxviruses [30].

Results

Disease progression—clinical signs and skin lesions

During the acclimation period, the goats remained clinically normal with rectal temperatures from 38.5 to 39.5 °C. Within three days after inoculation, all infected goats (8/8) developed a primary nodule, i.e., a 2–3 cm diameter subcutaneous swelling at the injection site.

Three goats (129, 335 and 373) developed hyperthermia from day 3 pi and the rectal temperature peaked at day 12 pi (average 41.3 °C) (Fig. 1). Focal skin nodules on eyelids, around the mouth and nose were observed by day 8 pi and generalized to the flanks, eyes, neck and hairless areas by day 10 pi (Fig. 2a–c). The nodules evolved into vesicles and crusts by day 14 pi. Bilateral oculo-nasal discharge with crusting around nares appeared by day 10 pi, followed by salivation at day 14 pi. Starting from day 7 pi, the goats showed decreased appetite and varying degrees of reduced activity. Once the animals developed clinical signs, they were monitored twice a day by veterinarians who ensured their feeding and watering. At day 15 pi, the three goats developed anorexia and became depressed; they were consequently euthanized within 24 h, i.e., at day 16 pi as improvement was not observed. At this stage, each goat had a total clinical scoring of 22 (Table 2).

In three other goats (261, 284 and 269), mild temperature increases were recorded from day 6 (39.5 °C). The following days, temperatures varied between 39.4 and 39.7 °C (Fig. 1). Small skin nodules appeared on the head and hairless areas at day 12 pi. The animals were euthanized at day 18 pi with a clinical score of 8 (Table 2). The uninfected control animals (759 and 267) remained healthy during the whole experiment.

Based on the severity of the clinical signs, infected goats were divided into 3 groups (G1–3),

G1: goats with severe clinical disease (animals 129, 335 and 373), G2: goats with moderate signs (animals 261, 284 and 269) and G3: goats with mild disease (animals 752 and 265).

The average clinical score per day was calculated for each group, showing a clear difference between the 3 inoculated groups regarding disease progression (Fig. 3). Goats from G1 showed the most severe disease and their clinical score reached 22. In the 2 other groups, clinical scores of individual animals did not exceed 16.

Gross pathology

The most severely affected goats (G1) showed prescapular and inguinal lymph node enlargement. At the injection site, the subcutaneous tissue appeared congested and edematous. Nodules and petechiae were observed in the skin of the head and flank. The mucous membranes of nares, mouth and eyelids were ulcerated. In goats of G1 and G2, the mesenteric lymph nodes were enlarged. The greater omentum was congested and had petechiae in goat 129 of G1 (Fig. 2d). The lungs did not show any gross pathology in any animal.
Fig. 2 Lesions following experimental infection of goats with a Vietnamese goatpox virus isolate. 

a, b Goats developed papules and nodules in the skin of head and ears. 

c Pox lesion with haemorrhagic papules on the ventral part of the tail and perineum. 

d Small intestine and mesentery with enlargement of mesenteric lymph nodes (arrow) and congestion of blood vessels.

### Table 2 Experimental days with highest clinical scoring after inoculation of goats with goatpox virus (n = 8) and controls (n = 2)

| Goat no. | Group 1<sup>a</sup> | Group 2<sup>a</sup> | Group 3<sup>a</sup> | Control |
|----------|---------------------|---------------------|---------------------|---------|
|          | 129 335 373         | 269 287 261         | 752 265             | 759 267 |
| Score    |                     |                     |                     |         |
| Post-infection day of highest score | 16 16 16 | 18 18 18 | 18 18 12 | 17  |
| Behavior | 3 3 3              | 2 2 1               | 1 1 1               | 0 0     |
| Feed-intake | 2 2 2          | 1 0 0               | 0 0 0               | 0 0     |
| Nodule at injection site | 3 3 3 | 3 3 3 | 2 2 0 | 0 0 |
| Temperature | 4 4 4          | 3 1 2               | 1 1 0               | 0 0     |
| Cutaneous lesions | 5 5 5        | 5 5 5               | 3 3 0               | 0 0     |
| Oculo-nasal discharge | 3 3 3 | 2 2 2 | 1 1 0 | 1 0 |
| Salivation | 2 2 2          | 0 0 0               | 0 0 0               | 0 0     |
| Total clinical scoring | 22 22 22 | 16 13 13 | 8 8 1 | 1 1 |

<sup>a</sup> Group 1, Group 2, Group 3: Inoculated goats were retrospectively divided into 3 groups, based on severity of clinical signs at the end of the experiment.
Virology and serology
Viral genome quantification results (expressed by cycle threshold (Ct)) are shown in Table 3. The highest DNA content was found in skin crusts (Ct 14.6), subcutaneous tissue at the injection site (Ct 19.4), secondary nodules (Ct 20.8) and trachea (Ct 22.9) in goats from G1. PCR analysis showed a lower viral load in the lung (Ct 35.7) and liver (Ct 35.1). There was no apparent difference in viral load between the groups. Blood tested negative for GTPV at all times.

VNT analyses of serum showed presence of antibodies on day 14 pi in all inoculated goats, with titers higher than 1.5 DN₅₀ (equivalent dilution 1/30) in 7/8 animals. The remaining goat (129 from G1) showed a weak response of 1.26 DN₅₀ (equivalent dilution 1/18). None of the control goats seroconverted.

GTPV was also detected by virus isolation on lamb testis cells from the subcutaneous tissue of a severely infected goat (335). Cytopathic effect appeared at day 4 pi and reached 80% at day 6 pi, consisting of clumping and rounding of cells in lysis plaques (Fig. 4).

Discussion
This is the first study on indigenous North African goat breed’s susceptibility to a virulent strain of GTPV. Three inoculated goats (G1) developed a severe disease, which lead to their euthanasia before the end of the experiment, while other goats displayed moderate

| Goat No. | Group 1 | Group 2 | Group 3 | Control |
|----------|---------|---------|---------|---------|
| Tissue   | Ct value|         |         |         |
| Subcutaneous tissue at injection site | 19.4 | 18.2 | 18.9 | 20.2 | 20.5 | NS | NS | NS | NS |
| Skin crusts | 16.6 | 16.6 | 16.5 | 18.3 | 14.9 | 14.6 | 17.1 | 17.3 | NS | NS |
| Secondary nodules | NS | NS | NS | 20.8 | 22.1 | 22.6 | 24.7 | 31.4 | NS | NS |
| Testis | NS | 19.1 | NS | 31.4 | NS | NS | NS | NS | NS | NS |
| Trachea | 22.9 | 25.6 | NS | 23.5 | 32.8 | 30.8 | 36.4 | 36.3 | – | – |
| Lung | – | – | – | 36.2 | – | – | 35.7 | – | – | – |
| Pulmonary lymph node | 29.9 | – | 36.2 | 33.7 | – | – | 31.8 | – | – | – |
| Heart | – | – | 34.9 | 34.1 | NS | NS | NS | NS | – | – |
| Spleen | – | – | NS | 32.1 | 34.4 | – | – | – | – | – |
| Liver | – | – | NS | – | – | – | 35.1 | – | – | – |
| Rumen | NS | NS | NS | 29.8 | NS | NS | NS | NS | NS | NS |
| Abomasum | 37.2 | – | NS | 35.1 | NS | NS | NS | NS | NS | NS |
| Reticulum | 30.8 | NS | NS | 29.3 | NS | NS | NS | NS | NS | NS |
| Omasum | 24.3 | 35.9 | NS | 29.8 | NS | NS | NS | NS | NS | NS |
| Duodenum | – | – | NS | 33.9 | – | NS | NS | NS | NS | NS |
| Mesenteric lymph node | 34.4 | – | NS | NS | 34.1 | 36.5 | 36.7 | 34.7 | – | – |
| Kidney | 34.7 | – | NS | – | – | – | – | – | – | – |
| Blood | – | – | – | – | – | – | – | – | – | – |

Tissues were sampled at day 16 (group 1) post infection (pi) or day 18 pi (group 2, group 3, Control)
NS not sampled
-- Negative, i.e. below detection level
* Group 1, Group 2, Group 3: Inoculated goats were retrospectively divided into 3 groups, based on severity of clinical signs at the end of the experiment
to mild clinical signs despite being of the same age and breed and inoculated with the same strain and dose. These results are similar to what was observed by Babiuk et al. [12] using the same virus strain, as severe clinical signs were observed in 3 of 9 experimentally infected Boer cross-bred goats. It seems that the GTPV strain causes a disease with varying degree of severity [29, 31], which has also been observed for the related LSDV [32, 33]. This may be explained by phylogenetic similarities between GTPV and LSDV [34, 35]. From our study, we can conclude that indigenous North African goats are as susceptible as other breeds if exposed to a virulent strain of GTPV.

The used clinical scoring represents a tool to quantify each stage of the disease in goats and can be used in challenge study for vaccine potency testing or to compare strain virulence and breed susceptibility. Clinical scorings have been also applied for bluetongue [36], African swine fever [37], peste des petits ruminants [38, 39] and lumpy skin disease [40]. The scoring allows us to compare the difference in clinical expression of the disease in goats, which could be attributed to individual susceptibility of the animals.

The clinical signs were similar to what was observed in other experimental GTPV infections of goats, and at necropsy, skin and mucosa of the oral cavity, nares and eyelids were affected, as also reported by Babiuk et al. [12] and Bowden et al. [29]. However, lesions in parenchymal organs such as spleen, liver and lungs were found in these studies, which was not the case in our experiment. Using PCR, high level of viral DNA was detected in the skin from where the virus was isolated, confirming subcutaneous tropism of GTPV [12, 29].

**Conclusion**

This study reproduced clinical goatpox in an indigenous North African goat breed using a virulent Vietnamese GTPV isolate and confirmed a susceptibility of this breed to GTPV. As indigenous goats are susceptible to GTPV, there is a high risk of spread of goatpox in North Africa if a virulent strain is introduced. Surveillance for goatpox should therefore be regularly conducted. A clinical scoring system was proposed to grade the severity of disease.

**Abbreviations**

CaPv: Capripoxvirus; CPE: CytoPathic effect; Ct: Cycle threshold; DN50: Dose neutralizing 50; GTPV: Goatpox virus; LSDV: Lumpy skin disease virus; OIE: World Organization for Animal Health; PBS: Phosphate buffered saline; pi: Post-infection; RPM: Rounds per minute; RT-qPCR: Real-time reverse transcriptase-polymerase chain reaction; qPCR: Quantitative polymerase chain reaction; SPPV: Sheeppox virus; TCID50: Tissue culture infective dose; VNT: Virus neutralization test.

**Acknowledgements**

All authors gratefully acknowledge Dr Henry Munyanduki for reviewing the manuscript and language editing.

**Authors’ contributions**

JH and ZB carried out the experiment, MJ performed the molecular biology analysis, MA participated in neutralization tests, JH performed the viral isolation and drafted the manuscript, NS reviewed the manuscript. KT and OF participated in the design and the follow up of the study, ME participated in the design of the study, manuscript drafting and data analysis and interpretation. All authors read and approved the final manuscript.

**Funding**

The study was funded by MCI Santé animale.
Availability of data and materials

The datasets used during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

Animal experiments were carried out in accordance with the international guidelines for care and handling of experimental animals described in chapter 7.8 of the Terrestrial Animal Health Code and Directive 2010/63/UE of the European commission (EU Commission, 2010; OIE and Terrestrial Animal Health Code, 2016). The protocol was approved by the Internal Ethics Committee for animal experiment in MCI santé animale (2018-MCI-013).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1 Department of Research and Development, Multi-Chemical Industry Santé Animale, Lot 157, Z 1, Sud-Ouest (ERAC) B.P: 278, 28810 Mohammedia, Morocco. 2 Department of Microbiology, Immunology and Contagious Diseases, Agronomic and Veterinary Institute Hassan II, Mladiat Al Ifrane, 6202 Rabat, Morocco.

Received: 10 February 2020 Accepted: 15 February 2021

Published online: 04 March 2021

References

1. Buller RM, Arif BM, Black DN, Dumbell KR, Esposito JJ, Lefkowitz EJ, et al. Poxviridae. In: Fauquet CM, Mayo MA, Maniloff J, Desselberger U, Ball LA, editors, et al. Virus taxonomy: eighth report of the international committee on the taxonomy of viruses. Oxford: Elsevier Academic Press; 2005. p. 117–33.

2. Tulman ER, Afonso CL, Lu Z, Zisk L, Sur JH, Sandybaev NT, et al. The genomes of sheeppox and goatpox viruses. J Virol. 2002;76:6054–61.

3. Kitching RP, Carn WM. Sheep pox and goat pox. Office International des Epizooties Manual of Diagnostic Tests and Vaccines for Terrestrial Animals (mammals, birds and bees). OIE, Paris, 2004; pp. 211–20.

4. Ramakrishnan MA, Santhamani R, Pandey AB. Capripox outbreak in a mixed flock of sheep and goats in India. Transbound Emerg Dis. 2016;64:27–30. https://doi.org/10.1111/tbed.12656.

5. Adedeji AJ, Dashe Y, Akanbi OB, Woma TY, Jambol AR, Adole JA, et al. Co- infection of poxvirus circulating in sheep and goat from outbreak cases of Aeda Berga district, West Shoa zone, central Ethiopia. MSc Thesis, College of Veterinary Medicine and Agriculture, Ethiopia, 2017.

6. Gallardo C, Soler A, Nieto R, Cano C, Pelayo V, Sanchez MA, et al. An HRM assay to differentiate sheeppox virus vaccine strains from wild sheeppox viruses. J Virol Methods. 2019;275:113752. https://doi.org/10.1016/j.jviromet.2019.113752.

7. Osuagwuh UI, Bagla V, Venter EH, Annandale CH, Irons PC. Absence of lumpy skin disease virus in semen of vaccinated bulls following vaccination and subsequent experimental infection. Vaccine. 2007;25:2238–43.

8. Annandale CH, Irons PC, Bagla VP, Osuagwuh UI, Venter EH. Sites of persistence of lumpy skin disease virus in the genital tract of experimentally infected bulls. Reprod Domest Anim. 2007;42:159–64. https://doi.org/10.1111/j.1439-0531.2006.01092.x.

9. Romanelli A, Laino D, De Martino M, Romeo A, Moscatello E, et al. A reliable and reproducible experimental challenge model for peste des petits ruminants virus. J Clin Microbiol. 2012;50:3738–40.
39. Bamouh Z, Fakri F, Jazouli M, Safini N, Tadlaoui KO, El Harrak M. Peste des petits ruminants pathogenesis on experimental infected goats by the Moroccan 2015 isolate. BMC Vet Res. 2019;15:452.
40. Carr VM, Kitching RP. The clinical response of cattle experimentally infected with lumpy skin disease (Neethling) virus. Arch Virol. 1995;140:503.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.